- September 22, 2021
- 9:00 AM - 4:30 PM ET
ABOUT THE PUBLIC WORKSHOP
The virtual public workshop will be held Wednesday, September 22, 2021, from 9:00 a.m. – 4:30 p.m. EDT. Discussions will include: Targeted Alpha Emitters with Focus on Actinium-225 Radiotherapies; Novel Radiopharmaceuticals: Standards Development, Product Quality, Supply and Demand; Clinical Considerations for Development of Novel Radiopharmaceuticals; User and Industry Perspectives.
The workshop will be conducted using Cisco WebEx. To participate in the WebEx workshop, please register by September 10, 2021 using the following event address: https://usnrc.webex.com/usnrc/onstage/g.php?MTID=ed88ca555fe84a004cc98c4e75ada3d40
ONLINE ATTENDANCE (WEBCAST)
This meeting will be broadcast live on the NRC’s Webcast portal at https://video.nrc.gov/. (Please note that the NRC’s Webcast portal will allow you to watch a live broadcast of the workshop. To ask panel discussion questions via chat or audio you must register for and attend the WebEx meeting.)
The Webcast (https://video.nrc.gov/) will be closed captioned.
REQUESTS FOR PUBLIC COMMENTS OR QUESTIONS
If you would like to submit questions to be considered by the workshop hosts and presenters, please submit them, any time before the event date, via email to ONDPublicMTGSupport@fda.hhs.gov.
For additional details, contact
Frank Lutterodt, Project Manager, DIRM,
Lisa Dimmick, Team Leader, Medical Radiation Safety,
Meeting Logistics: Sarah Lopas Sarah.Lopas@nrc.gov